



# Cybin Launches EMBARK and Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout and Distress with Psychedelic-Assisted Psychotherapy

6.8.21

-

-

EMBARK

is

aground-

breaking

psychotherapy

model



[Our Work](#)

[Investors](#)

[About Us](#)

leading  
clinical  
approaches  
to  
promote  
supportive  
healing  
with  
psychedelic  
medicine

-

-

**TORONTO,  
CANADA**

-

June  
8,  
2021

-

[Cybin](#)  
[Inc.](#)  
[\(NEO:CYBN\)](#)  
[\(OTCQB:CLXPF\)](#)

[Our Work](#)[Investors](#)[About Us](#)

the  
“**Company**”),  
a  
biotechnology  
company  
focused  
on  
progressing  
psychedelic  
therapeutics,  
today  
announced  
that  
it  
will  
co-  
sponsor  
a  
randomized,  
placebo-  
controlled  
trial  
of  
psychedelic-  
assisted



Our Work

Investors

About Us

psilocybin  
for  
frontline  
clinicians  
experiencing  
COVID-  
related  
distress.

The  
study  
will  
aim  
to  
treat  
symptoms  
of  
depression,  
anxiety,  
burnout  
and  
post-  
traumatic  
stress  
among  
frontline



[Our Work](#)

[Investors](#)

[About Us](#)

and  
healthcare  
professionals.

Cybin  
has  
formed  
a  
strategic  
collaboration  
with  
the  
University  
of  
Washington  
to  
help  
sponsor  
the  
trial,  
which  
will  
be  
led  
by



[Our Work](#)

[Investors](#)

[About Us](#)

Back.  
The  
study  
will  
be  
hosted  
in  
Seattle,  
a  
city  
hit  
hard  
with  
an  
early  
coronavirus  
outbreak.

“There  
is  
tremendous  
potential  
in  
a



Our Work

Investors

About Us

the  
University  
of  
Washington  
and  
Cybin  
to  
move  
the  
field  
forward,  
and  
this  
project  
is  
an  
incredibly  
valuable  
initial  
step  
towards  
a  
productive  
future,”  
said



[Our Work](#)

[Investors](#)

[About Us](#)

Back,  
who  
will  
serve  
as  
Primary  
Investigator  
to  
the  
clinical  
trial.

To  
support  
the  
initiative,  
Cybin's  
Chief  
Clinical  
Officer,  
Alex  
Belser,  
PhD  
and





[Our Work](#)

[Investors](#)

[About Us](#)

PhD  
(candidate)  
developed  
EMBARK.  
The  
development  
of  
EMBARK  
has  
been  
guided  
by  
leading  
process  
evidence  
for  
the  
clinical  
efficacy  
of  
psychedelic-  
assisted  
psychotherapy  
and  
demonstrated



[Our Work](#)

[Investors](#)

[About Us](#)

therapeutic

action

to

support

healing.

EMBARK

was

designed

as

a

transdiagnostic

psychotherapy

model

that

can

be

adapted

to

address

a

range

of

clinical

indications

and



Our Work

Investors

About Us

“Our  
nation’s  
doctors,  
nurses  
and  
clinicians  
have  
been  
shouldering  
the  
burden  
of  
COVID-  
19  
by  
taking  
care  
of  
the  
sickest  
among  
us.  
They’re  
experiencing



[Our Work](#)

[Investors](#)

[About Us](#)

of  
anxiety,  
depression  
and  
burnout.

Now

it's

our

turn

to

help

them,"

said

Dr.

Alex

Belser,

Cybin's

Chief

Clinical

Officer.

"We

are

sponsoring

research

to



[Our Work](#)

[Investors](#)

[About Us](#)

psychedelic  
medicine,  
when  
used  
with  
EMBARK's  
supportive  
therapy,  
can  
help  
clinicians  
recover  
from  
COVID-  
related  
distress."

Dr.  
Anthony

Back

is

a

recognized

leader

in



[Our Work](#)

[Investors](#)

[About Us](#)

of  
palliative  
care  
and  
oncology.  
He  
is  
a  
board-  
certified  
physician  
at  
the  
University  
of  
Washington,  
Founding  
Co-  
director  
of  
the  
University  
of  
Washington  
Center



[Our Work](#)

[Investors](#)

[About Us](#)

in  
Palliative  
Care,  
and  
a  
University  
of  
Washington  
professor  
of  
Oncology  
and  
Medicine.  
He  
is  
triple  
board  
certified  
in  
Hospice  
and  
Palliative  
Medicine,  
Medical  
Oncology



[Our Work](#)

[Investors](#)

[About Us](#)

Internal  
Medicine.  
He  
was  
the  
principal  
investigator  
for  
the  
National  
Cancer  
Institute-  
funded  
Oncotalk  
interventions,  
which  
enabled  
the  
founding  
of  
the  
nonprofit  
VitalTalk,  
co-  
wrote





[Our Work](#)

[Investors](#)

[About Us](#)

with  
Seriously  
III  
Patients,  
produced  
the  
first  
iPhone  
app  
for  
clinician  
communication  
skills,  
and  
is  
a  
Contemplative  
Studies  
Fellow  
of  
the  
Mind  
and  
Life  
Institute.



[Our Work](#)

[Investors](#)

[About Us](#)

and  
research  
interests  
include  
patient-  
physician  
communication  
and  
quality  
of  
life  
in  
palliative  
care.

Dr.  
Back  
earned  
his  
medical  
degree  
at  
Harvard  
Medical  
School.



[Our Work](#)

[Investors](#)

[About Us](#)

than  
a  
year  
now,  
frontline  
clinicians  
and  
healthcare  
professionals  
have  
made  
immeasurable  
sacrifices  
to  
protect  
public  
health  
in  
their  
communities.  
We  
consider  
it  
an  
honor



[Our Work](#)

[Investors](#)

[About Us](#)

duty  
to  
now  
help  
support  
their  
own  
healing  
processes,  
post-  
COVID-  
19.  
We  
are  
also  
delighted  
and  
proud  
to  
launch  
EMBARK,  
a  
ground-  
breaking  
psychotherapy



[Our Work](#)

[Investors](#)

[About Us](#)

at  
delivering  
best-  
practice,  
supportive  
healing  
in  
conjunction  
with  
psychedelic  
therapeutics.

We  
look  
forward  
to  
working  
with  
and  
supporting  
Dr.  
Anthony  
Back  
on  
this  
important



[Our Work](#)

[Investors](#)

[About Us](#)

Doug  
Drysdale,  
CEO  
of  
Cybin.  
Inc.

## **About Cybin**

Cybin  
is  
a  
leading  
biotechnology  
company  
focused  
on  
progressing  
psychedelic  
therapeutics  
by  
utilizing  
proprietary  
drug



[Our Work](#)

[Investors](#)

[About Us](#)

innovative  
drug  
delivery  
systems,  
novel  
formulation  
approaches  
and  
treatment  
regimens  
for  
psychiatric  
disorders.

**Cautionary  
Notes  
and  
Forward-  
Looking  
Statements**

Certain  
statements  
in  
this



[Our Work](#)

[Investors](#)

[About Us](#)

related  
to  
the  
Company  
are  
forward-  
looking  
statements  
and  
are  
prospective  
in  
nature.  
Forward-  
looking  
statements  
are  
not  
based  
on  
historical  
facts,  
but  
rather  
on





[Our Work](#)

[Investors](#)

[About Us](#)

and  
projections  
about  
future  
events  
and  
are  
therefore  
subject  
to  
risks  
and  
uncertainties  
which  
could  
cause  
actual  
results  
to  
differ  
materially  
from  
the  
future  
results



[Our Work](#)

[Investors](#)

[About Us](#)

implied  
by  
the  
forward-  
looking  
statements.

These  
statements  
generally  
can  
be  
identified  
by  
the  
use  
of  
forward-  
looking  
words  
such  
as  
“may”,  
“should”,  
“could”,  
“intend”,



Our Work

Investors

About Us

“anticipate”,

“expect”,

“believe”

or

“continue”,

or

the

negative

thereof

or

similar

variations.

Forward-

looking

statements

in

this

news

release

may

include

statements

regarding

enhanced

liquidity,



Our Work

Investors

About Us

of  
additional  
capital  
markets  
exposure,  
access  
to  
institutional  
and  
retail  
investors,  
the  
Company's  
new  
strategic  
brand  
messaging  
campaign,  
and  
psychedelic  
drug  
development  
programs  
to  
potentially

[Our Work](#)[Investors](#)[About Us](#)

health disorders. There are numerous risks and uncertainties that could cause actual results and Cybin's plans and objectives to differ materially from those expressed in



[Our Work](#)

[Investors](#)

[About Us](#)

looking  
information.

Actual  
results  
and  
future  
events  
could  
differ  
materially  
from  
those  
anticipated  
in  
such  
information.

These  
and  
all  
subsequent  
written  
and  
oral  
forward-  
looking



[Our Work](#)

[Investors](#)

[About Us](#)

based  
on  
estimates  
and  
opinions  
of  
management  
on  
the  
dates  
they  
are  
made  
and  
are  
expressly  
qualified  
in  
their  
entirety  
by  
this  
notice.  
Except  
as



Our Work

Investors

About Us

law,  
the  
Company  
does  
not  
intend  
to  
update  
these  
forward-  
looking  
statements.

Cybin  
makes  
no  
medical,  
treatment  
or  
health  
benefit  
claims  
about  
Cybin's  
proposed





[Our Work](#)

[Investors](#)

[About Us](#)

U.S.  
Food  
and  
Drug  
Administration,  
Health  
Canada  
or  
other  
similar  
regulatory  
authorities  
have  
not  
evaluated  
claims  
regarding  
psilocybin,  
psychedelic  
tryptamine,  
tryptamine  
derivatives  
or  
other  
psychedelic



[Our Work](#)

[Investors](#)

[About Us](#)

nutraceutical  
products.

The  
efficacy  
of  
such  
products  
has  
not  
been  
confirmed  
by  
approved  
research.

There  
is  
no  
assurance  
that  
the  
use  
of  
psilocybin,  
psychedelic  
tryptamine,



[Our Work](#)

[Investors](#)

[About Us](#)

or  
other  
psychedelic  
compounds  
or  
nutraceuticals  
can  
diagnose,  
treat,  
cure  
or  
prevent  
any  
disease  
or  
condition.  
Vigorous  
scientific  
research  
and  
clinical  
trials  
are  
needed.  
Cybin



[Our Work](#)

[Investors](#)

[About Us](#)

conducted  
clinical  
trials  
for  
the  
use  
of  
its  
proposed  
products.  
Any  
references  
to  
quality,  
consistency,  
efficacy  
and  
safety  
of  
potential  
products  
do  
not  
imply  
that



[Our Work](#)

[Investors](#)

[About Us](#)

such  
in  
clinical  
trials  
or  
that  
Cybin  
will  
complete  
such  
trials.  
If  
Cybin  
cannot  
obtain  
the  
approvals  
or  
research  
necessary  
to  
commercialize  
its  
business,  
it



Our Work

Investors

About Us

a  
material  
adverse  
effect  
on  
Cybin's  
performance  
and  
operations.

*The  
NEO  
Exchange  
has  
neither  
approved  
nor  
disapproved  
the  
contents  
of  
this  
news  
release*



Our Work

Investors

About Us

*not  
responsible  
for  
the  
adequacy  
and  
accuracy  
of  
the  
contents  
herein.*

**Investor**

**Contacts:**

Tim

Regan/Scott

Eckstein

KCSA

Strategic

Communications

[Cybin@kcsa.com](mailto:Cybin@kcsa.com)



[Our Work](#)

[Investors](#)

[About Us](#)

Wilson

In-

Site

Communications,

Inc.

[lwilson@insitecony.com](mailto:lwilson@insitecony.com)

**Media**

**Contacts:**

John

Kanakis

Cybin

Inc.

[John@cybin.com](mailto:John@cybin.com)

[PREVIOUS POST](#)

[NEXT POST](#)





Our Work

Investors

About Us



5600-100 King St W, Toronto ON  
 M5X 1C9  
 Investor Contact: [ir@cybin.com](mailto:ir@cybin.com)  
 General Contact:  
[info@cybin.com](mailto:info@cybin.com)

**Our Work**

[Development Pipeline](#)

[The Science](#)

[Cybin x Kernel](#)

**Investors**

[Press Releases](#)

[Financials](#)

[Corporate Governance](#)

[Downloads](#)

**About Us**

[Mission](#)

[Team](#)

[News](#)

[Join Us](#)

[Contact](#)

Copyright Cybin Corp. © 2021 . All rights reserved.

[Privacy Policy](#)